(MedPage Today) — SAN FRANCISCO — Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled with the addition of an investigational targeted therapy to standard treatment, a randomized…
Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/114212
Author :
Publish date : 2025-02-13 21:45:26
Copyright for syndicated content belongs to the linked Source.
